Excepts from “Cesium Therapy in Cancer Patients”
Treatment was performed on 50 patients during the last three years at Life Sciences Universal Medical Clinics in Rockville MD and in Washington D.C. All patients were terminal subjects with generalized metastatic disease. Forty-seven of the 50 patients studies had received maximal modalities of treatment, i.e., surgery, radiation, and various chemotherapy, before metabolic Cesium-treatment was initiated. Three patients were comatose and 14 of the patients were considered terminal due to previous treatments outcome and cancer complications.
The Cesium-treatment was given in conjunction of other supportive compounds under diet control in addition to the utilization of specific compounds to produce adequate circulation and oxygenation. According to individual cases Cesium Chloride was given at daily dosages of 6 to 9 grams in 3 equally divided doses, with vitamin A-emulsion (100,000 to 300,000 U), vitamin C (4 to 30 grams), zinc (80 to 100 mg) selenium (600 to 1,200 mcg) and amygdalin (1,500 mg) in addition to other supplementations according to the specific needs of the patient. The diet consisted mainly of whole grains, vegetables, linolenic acid rich oils (linseed, walnut, soy, wheat germ) and other supplemental food. To increase efficiency of the treatment and improve the circulation and oxygenation, the patients received the chelating agent EDTA, dimethylsulfoxide (DMSO) and also a combination of vitamin K and Mg salts.
The 50 cancer patients studied over 3 years had generalized metastatic disease, except for 3 patients. Initial death occurrences for the initial 2 week treatment was in the same order and magnitude of these recorded for the 12 month period. The percent of survival of breast, colon, prostate, pancreas, and lung cancer accounted to approximately, 50% recovery which was higher than that noted for liver cancer and the lymphoma patients treated. An overall 50% recovery from cancer by the Cesium-therapy was determined in the 50 patients treated. Data from the autopsy made indicated the absence of tumors in patient dying within 14 days of the Cesium-treatment. One of the most striking effects of the treatment was the disappearance of pain in all patients within 1 to 3 days after initiation of the Cesium-therapy.
These studies were performed under my direction, initiated in April, 1981. Twenty-eight patients were initially treated with Cesium Chloride between April, 1981 to October, 1982. They were subjected to various cancer therapies, e.g., surgery, radiation, and chemotherapy, and were considered terminal cases with metastatic disease except for 3 patients who were not previously treated. Three patients were comatose at the time of the Cesium treatment. Thirteen patients died within less than 2 weeks of treatment. Each patient showed a reduction in tumor mass by the Cesium-treatment. Of the breast cancer patients, the most impressive effect was seen on a female patient who was comatose at the beginning of the Cesium-treatment and was considered a terminal case. The Cesium-therapy, with other ingredients used, was immediately instituted by nasogastric route because there was no cooperation from the patient. The daily Cesium Chloride dose given amounted to 30 grams, 10 grams given 3 times daily. The patient was able to leave after 5 days of treatment. However the patient’s fall on the floor resulted in complications, i.e., fracture of the neck, and death. The autopsy revealed that the cancer metastasis had essentially eaten away her hip bone causing this tragic accident. The autopsy performed also showed the presence of very little cancer tissue.
The next most frequent cancer treated was of unknown primary. Treatment of 8 cases showed a death rate of 2 within 14 days of treatment and an additional 2 deaths within 12 months while 4 of the patients are still living. In one case, an autopsy was made in a patient after one week of Cesium-treatment and showed a complete disappearance of the cancer. There were 7 cases of colon cancer patients who were treated with Cesium Chloride. Two of these patients died within 14 days, one of the patients had previous massive chemotherapy, and little time was available to restore her metabolic condition. The previous existing infiltration of the abdominal wall disappeared. However, no consent was given for an autopsy.
In one lymphoma case the patient displayed an unusually large abdomen which was hard and he weighed approximately 250 pounds. The massively enlarged abdomen began to decline in volume, i.e., a loss of approximately 120 pounds of body weight was noted after 3 months of the Cesium- therapy. The spleen which was originally maximally enlarged and reaching into the pelvis was reduced to almost normal size. The liver position was down to about the level of the umbilicus and was also reduced to normal size in 3 months. The patient is still living after 3 years after his discharge. Unfortunately, there is no follow-up on this patient and he is being maintained on chemotherapy.
The results presented demonstrate the rate of efficacy of Cesium Chloride in cancer therapy. The total 50 cancer cases studied show an impressive 50% survival rate. This confirms the work of Messiha reported in these proceedings showing that the higher the dose it is, the more effective it seems to be. The autopsy obtained from the patient whose death was attributed to traumatic fracture of the neck, indicated that cancer had been initially further advanced resulting in bone destruction. However, the absence of cancer after the massive Cesium Chloride dose used in this case is demonstrable of the Cesium-therapy. It appears that both dosage, i.e., as much as 30 grams/day and route of drug administration, i.e., nasogastric pathway, might have contributed to the patients rapid recovery. It should be noted, however, that Cesium Chloride dose regimens should no exceed 20 to 40 grams due to side effects, mainly nausea, and diarrhea. The authors personal experience with Cesium Chloride after an acute dose of 40 prams Cesium Chloride indicate that extensive nausea and parethesia around the mouth are the major side effects. This is probably due to K depletion. The usual dose used in the clinic ranges from 2 to 3 grams given by mouth 3 times daily. At a later time, at which time there is no indication of cancer presence, the Cesium Chloride dosage will be reduced to a preventative dose between .5 and 1 gram a day.
The lymphoma case presented shows that Cesium Chloride efficiently reduced massive enlargements of spleen and liver as well as maximal ascites, causing an abdominal configuration of a tight, hard hemisphere, to almost normalize after 3 months of therapy. This period of time was required to eliminate such a massive volume resulting in the reduction of the body weight noted.
The clinical efficacy of Cesium Chloride high pH metabolic therapy is best demonstrated by a recent case of primary liver cancer (not included in the 50 cases reported in this study). The patient was a 39 year old female teacher who was terminal. She was brought on a stretcher on April 25, 1984 with a large liver tumor extending approximately 3 cm below the umbilical level. The treatment was then immediately instituted. This consisted of administration of Cesium Chloride, Beta-carotene, Vitamin C, Zn, Se, Mn, Cr, and K salts by the oral route in addition to a concomitant massive IV doses of ascorbate, K, Mg, Zn, Cn, Mn, Cr salts, B complex vitamins, folic acid, DMSO and heparin. After 5 consecutive treatment regimens EDTA was introduced to the therapy and the minerals present in the solution were discontinued. On May 10, 1984, the patient was discharged, returned home walking without assistance and displaying a smile on her face. The liver tumor had shrunk to 5 cm above the umbilicus. The determination of alphafetoprotein (AFP), a specific marker for liver cancer, rare embronal cancer and teratomas, decreased from the unusually high value of 39,000 units, compared to normal levels of 13 units, measured before initiation of Cesium-therapy, to 5000 units obtained on the last day of treatment.
The mechanism of action of Cesium in cancer has been little studied. That both Cs+ and Rb+ can specifically enter the cancer cells and embryonic cells but not normal adult cells has been demonstrated by Brewer. The cancer cells contain high amounts of hydrogen ions rendering them acidic and they also contain high Na+ levels than found in normal cells. If Cs+ or Rb+ can enter the cancer cells then the pH increases from as low as 5.5 to over pH 7.0. At a pH of 7.6 the cancer cell division will stop, at a pH of 8.0 to 8.5 the lifespan of it is considerably shortened (only hours). In one case, the author has observed the shrinkage of metastases of breast cancer after one hour of Cesium-treatment. Two days later wrinkles of the skin appeared where the tumor was present. In another case of a colon cancer with massive metastasis, of massive infiltration of the abdominal wall, liver and other tissues, seemed to have been reduced within 24 hours and continuing rapidly until the demise of the patient on the 14th day of the Cesium-treatment.
The uric acid levels measured at the onset of treatment was approximately 3.5 units which was increased to over 20 units, suggesting massive breakdowns of DNA, which produces the uric acid output. Therefore, destruction of nuclear acids, as reflected by a significant rise in the uric acid, may be used as a predictive measurement for treatment outcome. The failure of uric acid elevation may be indicative of lack of destruction of cancer cells. This has proven to be a very consistent finding in our clinic.
Source: Cesium Therapy in Cancer Patients
Copyright killcancercells.com. All rights reserved. For personal use only.